ImmunoACT
PrivateLast Round
Series B
May 31, 2023
Est. Valuation
$133.61M
Total Funding Raised
$19.99M
Company Overview
ImmunoACT operates in Healthcare & Life Sciences and is based in Navi Mumbai. Its latest recorded funding round was a Series B round in May 2023.
ImmunoACT is a biotechnology company that develops and commercializes affordable CAR-T cell therapies for the treatment of various blood cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoACT Comparables
Compare ImmunoACT with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immuneel Therapeutics | 92% | |
| Cellogen Therapeutics | 82% | |
| JW Therapeutics | 77% |
For institutional investors. Book with your work email.
ImmunoACT Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 31, 2023 | ||||
| Series A | Nov 19, 2021 | ||||
| Grant | Mar 8, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ImmunoACT Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Biotechnology Industry Research Assistance Council | Grant |
| Tata Trusts | Grant |
| Society for Innovation and Entrepreneurship | Accelerator, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 1, 2025
Presented NexCAR19 CAR-T therapy at ESTIC 2025.
- Feb 1, 2025
Launched NexCAR19, India's first indigenous CAR-T therapy.
For institutional investors. Book with your work email.
ImmunoACT Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImmunoACT's valuation, stock price, and market status.
Is ImmunoACT a public or private company?
ImmunoACT is a private company.
What is the current stock price of ImmunoACT?
ImmunoACT is a private company, so its shares have no public market price. Caplight tracks ImmunoACT's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmunoACT worth (valuation)?
ImmunoACT's valuation is estimated at $133.6M based on funding round data.
Can I buy ImmunoACT stock?
ImmunoACT shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmunoACT's last funding round?
ImmunoACT's most recent funding round was Series B on May 31, 2023.
Who are the main investors in ImmunoACT?
Key investors in ImmunoACT include Society for Innovation and Entrepreneurship.
Will ImmunoACT IPO soon?
No public IPO plans have been announced for ImmunoACT.
How can I track ImmunoACT secondary market activity?
Caplight tracks bids, offers, and trades in ImmunoACT's shares on secondary markets.